Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR1188-ABC in KRAS-mutated Cancers
NCT07594067Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Dec 2026
- Primary completion
- Nov 2042
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TCR1188-ABC cells in pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA), colorectal cancer (CRC) and 1 more (4 arms), sponsored by University of Pennsylvania. Primary endpoints: Adverse Events at 15 years, Dose-Limiting Toxicities at 28 days and 1 more. Planned start Dec 2026; status: recruiting.
02
Drugs
TCR1188-ABC cells
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07594067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594067.